Tim Iveson, MD, FACP, medical oncologist, University Hospital Southampton NHS Foundation Trust, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

In the trial, 3273 patients received CAPOX or FOLFOX, which was decided by the treating physician. Patients were then randomized to receive the chemotherapy for 3 months versus 6 months.

Results showed there were more adverse events (AEs) in patients who received 6 months of treatment versus patients who received 3 months of treatment across all AEs, particularly diarrhea and peripheral neuropathy. The rate of peripheral neuropathy in patients with 3 months of treatment was 13.0% versus 36% in patients who received 6 months treatment. Additionally, 5-year disease-free survival, which was the primary endpoint, was 80.7% for patients who received 3 months of chemotherapy versus 83.9% for patients who received 6 months of chemotherapy.

Videos

Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

Tim Iveson, MD, FACP

Articles

Dr. Iveson on the IDEA Collaboration in CRC